Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19: Azelastine Nasal Spray in Early COVID-19
DRKS00028829Phase 3Completed
- Sponsor
- URSAPHARM
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Azelastine 0.1% nasal spray with Placebo nasal spray (2 arms). Primary endpoints: Reduction in COVID-19 symptoms and Hospitalization rate. Started Apr 2022; status: completed.
02
Drugs
azelastine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on DRKS00028829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00028829.